AdvisorNet Financial Inc Lowers Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AdvisorNet Financial Inc trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 22.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 78 shares of the biopharmaceutical company’s stock after selling 22 shares during the quarter. AdvisorNet Financial Inc’s holdings in Regeneron Pharmaceuticals were worth $56,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Fairfield Financial Advisors LTD purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $37,000. Truvestments Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $39,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $42,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ:REGN opened at $681.58 on Friday. The company has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. The firm’s 50-day simple moving average is $738.60 and its 200-day simple moving average is $949.99. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $666.25 and a fifty-two week high of $1,211.20.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Sanford C. Bernstein lowered their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Citigroup cut their price objective on Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating for the company in a research report on Tuesday, January 14th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.